A randomized phase IB/IIA study of CApecitabine plus Radium-223 (Xofigo) in breast cancer patients with BONe metastases (CARBON)
Phase of Trial: Phase I/II
Latest Information Update: 14 Jul 2016
At a glance
- Drugs Capecitabine (Primary) ; Radium 223 chloride (Primary)
- Indications Breast cancer
- Focus Adverse reactions; Therapeutic Use
- Acronyms CARBON
- Sponsors Bayer HealthCare
- 19 May 2016 Status changed from not yet recruiting to recruiting.
- 07 Apr 2016 Planned initiation date changed from 1 Mar 2015 to 30 May 2016 as per ISRCTN: Current Controlled Trials record.
- 07 Apr 2016 Status changed from recruiting to not yet recruiting as per ISRCTN: Current Controlled Trials record.